AIM Biologicals System Does Well in Early NMOSD Tests

Autoimmunity Modifying (AIM) Biologicals, an experimental platform that Aeterna Zentaris is developing to treat autoimmune diseases like neuromyelitis optica spectrum disorder (NMOSD), showed proof-of-concept activity in cell and mouse models of NMOSD, new data show. The findings were presented at the 13th International Congress on Autoimmunity, held earlier…

Aeterna Buys Promising Targeted Immunosuppressive Therapy Platform

Aeterna Zentaris GmbH has acquired exclusive global rights to develop, manufacture, and commercialize highly-specific, autoimmune modifying proteins for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The company, a subsidiary of Aeterna Zentaris, reached an agreement with Julius-Maximilians-University Wuerzburg (JMU), in Germany, which developed the technology, called AIM Biologicals.